Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. announced a change in the shareholding interests due to a shift in the general partners of its employee shareholding platforms. This change led to a decrease in the combined shareholding interests of key executives, including Dr. LOU, Mr. LOU, and Ms. ZHENG, from approximately 19.36% to 18.18%, potentially impacting the company’s governance dynamics and stakeholder interests.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, providing a range of services including drug discovery, development, and manufacturing. The company focuses on offering integrated solutions to pharmaceutical and biotech companies worldwide.
YTD Price Performance: 13.05%
Average Trading Volume: 9,194,208
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.67B
For detailed information about 3759 stock, go to TipRanks’ Stock Analysis page.